ISRCTN45483324 https://doi.org/10.1186/ISRCTN45483324

A strategy to immunize young infants against measles

Submission date	Recruitment status	[_] Prospectively registered
15/09/2005	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
03/11/2005	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
28/10/2021	Infections and Infestations	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Hilton Whittle

Contact details
MRC Laboratories
Fajara
Gambia
PMB243
+220 4496715
hwhittle@mrc.gm

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
SCC 948

Study information

Scientific Title
A strategy to immunize young infants against measles

Study objectives
Immunogenicity of Edmonston-Zagreb measles vaccine given at 4 and 9 months of age will be superior to that of the vaccine given at 9 months of age

Ethics approval required
Old ethics approval format

Ethics approval(s)
Added as of 30/07/2007:
This trial was approved by:
1. The Gambia Government / Medical Research Council Ethics Committee
2. The London School of Hygiene and Tropical Medicine

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Prevention

Participant information sheet

Health condition(s) or problem(s) studied
Measles

Interventions
Edmonston-Zagreb measles vaccine given at 4 and 9 months of age versus vaccine given at 9 months of age

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Edmonston-Zagreb measles vaccine

Primary outcome measure

Gamma interferon elispot counts after stimulation of peripheral blood mononuclear cells with measles virus at 18 months of age

Secondary outcome measures
Measles haemagglutinin inhibiting antibody at 18 months of age

Overall study start date
02/07/2003

Completion date
31/12/2005

Eligibility

Key inclusion criteria
Healthy children whose parents agree to the trial

Participant type(s)
Patient

Age group
Child

Sex
Both

Target number of participants
150

Total final enrolment
132

Key exclusion criteria
Malnourished children or those with a febrile illness

Date of first enrolment
02/07/2003

Date of final enrolment
31/12/2005

Locations

Countries of recruitment
Gambia

Study participating centre

MRC Laboratories
Fajara
Gambia
PMB243

Sponsor information

Organisation
Medical Research Council (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
markpalmer@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

ROR
https://ror.org/03x94j517

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (SCC948)(UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results at 3 year booster	28/03/2012	28/10/2021	Yes	No